Those treated with erenumab also had a greater average reduction in MMDs in several secondary endpoints. For those on erenumab, there was an overall mean difference of –1.61 MMDs, compared with placebo. Erenumab-treated patients also had an overall mean difference of –1.73 acute medication days, compared with placebo.
The authors reported that erenumab had safety and tolerability comparable to placebo, and none of the patients taking erenumab discontinued because of adverse events.
Dr. Reuter cautioned that additional studies will need to be conducted to determine if the effects last longer than 3 months and to identify patients most likely to respond.
The study was funded by Novartis, which is developing erenumab.
SOURCE: Reuter E et al. AAN 2018, Emerging Science Abstract 009.